Yumiko Matsuo

Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults

Ryosuke Shimizu, Takuhiro Sonoyama, Takahiro Fukuhara et al. · Antimicrobial Agents and Chemotherapy · 2022 · 69 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

Evaluation of the Drug–Drug Interaction Potential of Ensitrelvir Fumaric Acid with Cytochrome P450 3A Substrates in Healthy Japanese Adults

Ryosuke Shimizu, Takuhiro Sonoyama, Takahiro Fukuhara et al. · Clinical Drug Investigation · 2023 · 38 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

A Phase 1 Study of Ensitrelvir Fumaric Acid Tablets Evaluating the Safety, Pharmacokinetics and Food Effect in Healthy Adult Populations

Ryosuke Shimizu, Takuhiro Sonoyama, Takahiro Fukuhara et al. · Clinical Drug Investigation · 2023 · 23 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacology +17

Glucuronidation Converting Methyl 1-(3,4-Dimethoxyphenyl)-3-(3-ethylvaleryl)-4-hydroxy-6,7,8-trimethoxy-2-naphthoate (S-8921) to a Potent Apical Sodium-Dependent Bile Acid Transporter Inhibitor, Resulting in a Hypocholesterolemic Action

Shingo Sakamoto, Hiroyuki Kusuhara, Kenji Miyata et al. · Journal of Pharmacology and Experimental Therapeutics · 2007 · 22 citations

Life Sciences, Medicinal Chemistry, Pharmacology +16

Transport of Quinolone Antibacterial Drugs in a Kidney Epithelial Cell Line, LLC-PK1

Yumiko Matsuo, Ikuko Yano, Tatsuya Ito et al. · Journal of Pharmacology and Experimental Therapeutics · 1998 · 22 citations

Medicine, Cell Biology, Pharmacology +17